✦ LIBER ✦

185 Anti-tumor activity of CU-201, an inhibitor of HDAC, SFK and Abl kinases

✍ Scribed by R. Bao; C. Lai; H. Qu; D. Wang; L. Ying; X. Tao; J. Wang; H. Zhai; H. Cai; C. Qian

Book ID: 119602866
Publisher: Elsevier Science
Year: 2010
Tongue: English
Weight: 44 KB
Volume: 8
Category: Article
ISSN: 1359-6349
DOI: 10.1016/s1359-6349(10)71890-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Activity of histone deacetylase inhibito

Activity of histone deacetylase inhibitors and an Aurora kinase inhibitor in BCR-ABL-expressing leukemia cells: Combination of HDAC and Aurora inhibitors in BCR-ABL-expressing cells

✍ Seiichi Okabe, Tetsuzo Tauchi, Yuko Tanaka, Shinya Kimura… 📂 Article 📅 2013 🏛 BioMed Central 🌐 English ⚖ 343 KB

Preclinical anti-angiogenesis and anti-t

Preclinical anti-angiogenesis and anti-tumor activity of SIM010603, an oral, multi-targets receptor tyrosine kinases inhibitor

✍ Dongchun Wang; Feng Tang; Sen Wang; Zhenzhou Jiang; Luyong Zhang 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 563 KB

Anti-tumor activity of the combination o

Anti-tumor activity of the combination of cetuximab, an anti-EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases

✍ Maria Pia Morelli; Tina Cascone; Teresa Troiani; Concetta Tuccillo; Roberto Bian 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 200 KB

## Abstract Purpose: The epidermal growth factor receptor (EGFR) autocrine pathway plays an important role in cancer cell growth. Vascular endothelial growth factor A (VEGF‐A) is a key regulator of tumor‐induced endothelial cell proliferation and vascular permeability. ZD6474 is an orally available

148 BAY 57-9352: an inhibitor of VEGFR-2

148 BAY 57-9352: an inhibitor of VEGFR-2 and PDGFR receptor tyrosine kinases that demonstrates broad anti-tumor activity as a single agent in preclinical models

✍ Y. Chang; C. Cortes; C. Brink; B. Polony; P. Vincent; D. Xue; D. Wilkie; A. McNa 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 148 KB